Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | RBP4 | P02753 | 3/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CALCA | P06881 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3929552 | 0.90 | HDAC4 (0.32) | PDE9AGRM2NPC1ALDH1A1RAB9A | |
| SCHEMBL3922269 | 0.90 | APLNR (0.33) | PDE9AGRM2NPC1ALDH1A1RAB9A | |
| SCHEMBL3921538 | 0.87 | CYP3A4 (0.34) | PDE9AKDM4EHSD17B10NPC1RAB9A | |
| SCHEMBL3920916 | 0.85 | NTSR1 (0.34) | — | |
| SCHEMBL3935055 | 0.84 | CHIT1 (0.39) | KDM4ENPC1RAB9A | |
| SCHEMBL3933865 | 0.82 | PDE9A (0.36) | PDE9AGRM2ALDH1A1CDK2DRD4 | |
| SCHEMBL3931669 | 0.82 | NAPEPLD (0.39) | — | |
| SCHEMBL5144275 | 0.82 | PDE10A (0.35) | PDE9AKDM4EGRM2 | |
| SCHEMBL3920661 | 0.82 | NPC1 (0.37) | KDM4EGRM2NPC1ALDH1A1RAB9A | |
| SCHEMBL3930973 | 0.80 | ROCK2 (0.44) | GRM2NPC1ALDH1A1RAB9ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051980-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | PDE9A 4447/4885KDM4E 1939/4885RBP4 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.